Objective:

To explore the pressures faced by biopharma companies in transitioning therapies from discovery to clinical and commercial readiness.

Approach:

• Kevin Schaab, Sr. Drug Development Consultant: Identifies pressure at the preclinical-to-clinical transition, emphasizing the need for safety, tolerability, and early patient trial pathways.
• David Claveau, Vice President, Business Development, North America, Sygnature Di…: Highlights the importance of decision quality under time and capital constraints, advocating for integrated discovery to improve data generation.
• Jeremy Skillington, CEO, Poolbeg Pharma: Discusses the critical nature of funding and the impact of development stage on financial requirements, noting recent large investments.
• Alison Clayton, Strategic Projects Director, Symbiosis Pharmaceutical Services: Addresses the challenge of balancing speed with long-term commercial readiness, particularly for complex biologics.
• Cora Griffin, Head of Business Development, Curve Therapeutics Ltd: Points out capital efficiency as a major pressure, especially for emerging biotechs facing funding disparities.
• Jane Rhodes, CEO, AstronauTx: Emphasizes the challenge of clinical translation and the need for reliable measures of clinical benefit amid budget constraints.

Key Findings:

• The preclinical-to-clinical transition is a critical pressure point requiring demonstration of safety and tolerability.
• Emerging companies face high capital risk and must show credible paths to differentiation.
• Funding is essential, with companies needing to reach milestones to unlock further investment.
• Balancing speed with long-term readiness is crucial in a competitive environment.
• Capital efficiency is a significant concern, especially for emerging biotechs in a tight funding landscape.
• Clinical translation remains a challenge due to high attrition rates and budget constraints.

Interpretation:

Limitations:

• Resource constraints limit the ability of emerging biotechs to manage complex development programs.
• High attrition rates in clinical trials hinder the translation of preclinical success.

Conclusion:

The biopharma industry faces multifaceted pressures that require a holistic approach to development and funding.